Angela Vollstedt
Director, Global R&D Cell & Gene Therapies Portfolio Novartis
Angela Vollstedt, PhD, MBA is Director of the Global R&D Cell & Gene Therapies Portfolio at Novartis, where she leads strategic asset, portfolio, and lifecycle initiatives across advanced therapies. With more than 20 years of experience spanning development, manufacturing, regulatory strategy, and commercialization, she brings a unique system-level perspective on translating scientific innovation into scalable patient access.
Seminars
Wednesday 10th February 2027
Building Cost-Effective Solutions for Complex Manufacturing Processes
11:45 am
- Identifying the greatest cost drivers across development and manufacturing to proactively build a sustainable path to commercialisation
- Designing flexible manufacturing strategies to enable speed or COGs innovations that don’t disrupt regulatory approval or proof of comparability
- Leveraging established pipelines to utilise similar CAR constructs across indications to reduce manufacturing changes, cost and regulatory push-back
